Home Alzheimer’s Disease Study Identifies Oncology Health Professionals’ Conflicting Perceptions of Telehealth

Study Identifies Oncology Health Professionals’ Conflicting Perceptions of Telehealth

A study published in JAMA Network Open highlighted the conflicting opinions of oncologic health care professionals regarding telehealth and gave insight into potential barriers which need to be further investigated or improved for the expansion and continued utilization of the virtual service.

These results are particularly relevant given the continued effects of the coronavirus disease 2019 (COVID-19) pandemic, which has forced institutions worldwide to design or expand telehealth programs.

“While it remains unclear how long these changes will last, COVID-19 has ushered in a new era for telehealth services, and further research regarding the barriers to offering them due to perceived financial impact is necessary,” wrote the study authors, who were led by Arianna Heyer.

In this qualitative study, investigators used interviews conducted with medical oncology health professionals at…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Women of Minority Race/Ethnicity, Lower Socioeconomic Status Experience Lower Digital Breast Tomosynthesis Access

A cross-sectional study of digital breast tomosynthesis (DBT) screening published in JAMA Network Open indicated that women of minority race/ethnicity and lower socioeconomic status...

Michael Szarek, PhD, on the Outcomes of a Q-TWiST Analysis From the Phase 3 TIVO-3 Study

An analysis revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in...

Recent Comments